• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ErbB3 配体 heregulin1 是失控肺癌细胞增殖的主要有丝分裂因子。

ErbB3 Ligand Heregulin1 Is a Major Mitogenic Factor for Uncontrolled Lung Cancer Cell Proliferation.

机构信息

Department of Basic Research, Sichuan Cancer Hospital/Institute, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610041.

Department of Pathology, Sichuan Cancer Hospital/Institute, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610041.

出版信息

Neoplasia. 2019 Apr;21(4):343-352. doi: 10.1016/j.neo.2019.02.001. Epub 2019 Mar 2.

DOI:10.1016/j.neo.2019.02.001
PMID:30831376
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6403265/
Abstract

There are seven ligands for the epidermal growth factor receptor (EGFR) ErbB1 and two ligands for ErbB3. EGFR can form a homodimer or a heterodimer with ErbB3. In this study, we investigated whether homodimers or heterodimers, and which ligand, play a major role in cancer development, with the goal of ultimately identifying therapeutic targets. We demonstrated that the ErbB3 ligand heregulin1 is the strongest mitogenic factor for non-small cell lung cancer cells and is more potent in activating EGFRmut-ErbB3 heterodimers than EGFRwt-ErbB3 heterodimers. We discovered that four of the seven EGFR ligands inhibited heregulin1-induced EGFRwt-ErbB3 activation and cell proliferation by promoting dephosphorylation of heregulin1-induced ErbB3 phosphorylation, whereas the other three did not exhibit such inhibition. Importantly, those four EGFR ligands did not inhibit heregulin1-induced EGFRmut-ErbB3 activation and proliferation of cells with EGFR mutants. We demonstrated that ErbB3 was overexpressed in the lung cancer cells but not in the adjacent normal alveoli or stromal tissue. EGFR and heregulin1 were also highly expressed in lung cancer cells. We conclude that the overexpression of heregulin1, ErbB3, and EGFR mutant renders uncontrolled cell proliferation.

摘要

表皮生长因子受体 (EGFR) ErbB1 有七种配体,ErbB3 有两种配体。EGFR 可以与 ErbB3 形成同源二聚体或异源二聚体。在这项研究中,我们研究了同源二聚体或异源二聚体,以及哪种配体在癌症发展中起主要作用,最终目的是确定治疗靶点。我们证明了 ErbB3 配体 heregulin1 是非小细胞肺癌细胞最强的有丝分裂因子,并且比 EGFRwt-ErbB3 异源二聚体更能激活 EGFRmut-ErbB3 异源二聚体。我们发现,七种 EGFR 配体中的四种通过促进 heregulin1 诱导的 ErbB3 磷酸化去磷酸化,抑制了 heregulin1 诱导的 EGFRwt-ErbB3 激活和细胞增殖,而另外三种则没有表现出这种抑制作用。重要的是,这四种 EGFR 配体没有抑制 EGFR 突变体的 heregulin1 诱导的 EGFRmut-ErbB3 激活和细胞增殖。我们证明了 ErbB3 在肺癌细胞中过度表达,但在相邻的正常肺泡或基质组织中没有表达。EGFR 和 heregulin1 在肺癌细胞中也高度表达。我们得出结论,过度表达的 heregulin1、ErbB3 和 EGFR 突变体导致不受控制的细胞增殖。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/c8701562e1f5/gr20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/16c1432a331c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/b8f3080db9a4/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/c89f2856e0c8/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/82e6752231db/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/a56ef4a89a27/gr5a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/0b305648f27a/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/7a8f7000b116/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/7cafb0a3be6e/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/f4298db92e14/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/c38f1e234679/gr14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/3041b8694ae1/gr15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/9cd9620de3a0/gr19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/c8701562e1f5/gr20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/16c1432a331c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/b8f3080db9a4/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/c89f2856e0c8/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/82e6752231db/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/a56ef4a89a27/gr5a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/0b305648f27a/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/7a8f7000b116/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/7cafb0a3be6e/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/f4298db92e14/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/c38f1e234679/gr14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/3041b8694ae1/gr15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/9cd9620de3a0/gr19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffd/6403265/c8701562e1f5/gr20.jpg

相似文献

1
ErbB3 Ligand Heregulin1 Is a Major Mitogenic Factor for Uncontrolled Lung Cancer Cell Proliferation.ErbB3 配体 heregulin1 是失控肺癌细胞增殖的主要有丝分裂因子。
Neoplasia. 2019 Apr;21(4):343-352. doi: 10.1016/j.neo.2019.02.001. Epub 2019 Mar 2.
2
The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner.癌蛋白 ErbB3 在没有外加配体的情况下,通过网格蛋白依赖的方式被内吞。
Carcinogenesis. 2012 May;33(5):1031-9. doi: 10.1093/carcin/bgs128. Epub 2012 Mar 20.
3
Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.抗表皮生长因子受体抗体促进ErbB2/ErbB3异二聚体形成从而刺激非小细胞肺癌细胞系生长。
Mol Cancer Res. 2007 Apr;5(4):393-401. doi: 10.1158/1541-7786.MCR-06-0303.
4
ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers.ErbB3信使核糖核酸的表达与日本肺癌的特定临床病理特征相关。
J Surg Res. 2008 May 1;146(1):43-8. doi: 10.1016/j.jss.2007.05.030. Epub 2007 Jul 13.
5
ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.ErbB3的表达以及与表皮生长因子受体(EGFR)的二聚化作用会影响胰腺癌细胞对厄洛替尼的敏感性。
Cancer Biol Ther. 2007 Apr;6(4):548-54. doi: 10.4161/cbt.6.4.3849.
6
Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.双重靶向 ERBB2/ERBB3 治疗 SLC3A2-NRG1 介导的肺癌。
Mol Cancer Ther. 2018 Sep;17(9):2024-2033. doi: 10.1158/1535-7163.MCT-17-1178. Epub 2018 Jun 29.
7
Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling.配体依赖性信号传导中,激活的和非对称磷酸化的 ERBB2 和 ERBB3 异源二聚体作为支架的功能隔离。
Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13237-42. doi: 10.1073/pnas.1200105109. Epub 2012 Jun 25.
8
A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.一种新的模型系统将表皮生长因子受体-人表皮生长因子受体2(HER2)以及HER2-人表皮生长因子受体3异二聚体识别为食管上皮细胞侵袭的强效诱导剂。
J Pathol. 2017 Dec;243(4):481-495. doi: 10.1002/path.4987. Epub 2017 Nov 5.
9
Discovery of ERBB3 inhibitors for non-small cell lung cancer (NSCLC) via virtual screening.通过虚拟筛选发现用于非小细胞肺癌(NSCLC)的ERBB3抑制剂。
J Mol Model. 2016 Jun;22(6):135. doi: 10.1007/s00894-016-3007-z. Epub 2016 May 17.
10
Epidermal growth factor mutant with wild-type affinity for both ErbB1 and ErbB3.对ErbB1和ErbB3均具有野生型亲和力的表皮生长因子突变体。
Biochemistry. 2006 Apr 11;45(14):4703-10. doi: 10.1021/bi060087m.

引用本文的文献

1
Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer.克服表皮生长因子受体(EGFR)突变型肺癌对奥希替尼耐药的策略
Int J Mol Sci. 2025 Mar 25;26(7):2957. doi: 10.3390/ijms26072957.
2
HER3 Alterations in Cancer and Potential Clinical Implications.癌症中的HER3改变及其潜在临床意义。
Cancers (Basel). 2022 Dec 14;14(24):6174. doi: 10.3390/cancers14246174.
3
Targeting HER3-dependent activation of nuclear AKT improves radiotherapy of non-small cell lung cancer.针对 HER3 依赖性核 AKT 的激活可改善非小细胞肺癌的放射治疗。

本文引用的文献

1
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways.一组获批抗体通过阻断旁路途径克服肺癌对奥希替尼的耐药性。
Clin Cancer Res. 2018 Nov 15;24(22):5610-5621. doi: 10.1158/1078-0432.CCR-18-0450. Epub 2018 Jul 2.
2
Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.表皮生长因子受体突变状态和表皮生长因子受体酪氨酸激酶抑制剂对非小细胞肺腺癌脑转移立体定向放射外科疗效的影响:133 例连续患者的回顾性分析。
Lung Cancer. 2018 May;119:120-126. doi: 10.1016/j.lungcan.2018.03.013. Epub 2018 Mar 14.
3
Radiother Oncol. 2022 Sep;174:92-100. doi: 10.1016/j.radonc.2022.07.008. Epub 2022 Jul 15.
4
Germline ERBB3 mutation in familial non-small-cell lung carcinoma: expanding ErbB's role in oncogenesis.家族性非小细胞肺癌中的胚系 ERBB3 突变:扩展 ErbB 在肿瘤发生中的作用。
Hum Mol Genet. 2021 Nov 30;30(24):2393-2401. doi: 10.1093/hmg/ddab172.
5
Mucinous adenocarcinoma caused by cancerization from a ciliated multinodular papilloma tumor: A case report.黏液性腺癌源于纤毛多结节乳头状瘤肿瘤的癌变:病例报告。
Thorac Cancer. 2021 May;12(10):1629-1633. doi: 10.1111/1759-7714.13956. Epub 2021 Apr 3.
6
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.靶向HER3(一种催化缺陷型受体酪氨酸激酶)可预防肺癌对第三代EGFR激酶抑制剂产生耐药性。
Cancers (Basel). 2020 Aug 24;12(9):2394. doi: 10.3390/cancers12092394.
Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model".
通过配体结合和致癌突变激活表皮生长因子受体:“旋转模型”
Cells. 2017 Jun 2;6(2):13. doi: 10.3390/cells6020013.
4
EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms.EGF 和 NRG 通过 EGFR 以不同的寡聚化机制诱导 HER3/ERBB3 的磷酸化。
Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2836-E2845. doi: 10.1073/pnas.1617994114. Epub 2017 Mar 20.
5
Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.非小细胞肺癌细胞中 EGFR 野生型等位基因的扩增导致对突变选择性 EGFR 酪氨酸激酶抑制剂的获得性耐药。
Cancer Res. 2017 Apr 15;77(8):2078-2089. doi: 10.1158/0008-5472.CAN-16-2359. Epub 2017 Feb 15.
6
EGF receptor ligands: recent advances.表皮生长因子受体配体:最新进展
F1000Res. 2016 Sep 8;5. doi: 10.12688/f1000research.9025.1. eCollection 2016.
7
Effects of different ligands on epidermal growth factor receptor (EGFR) nuclear translocation.不同配体对表皮生长因子受体(EGFR)核转位的影响。
Biochem Biophys Res Commun. 2016 Sep 9;478(1):39-45. doi: 10.1016/j.bbrc.2016.07.097. Epub 2016 Jul 25.
8
Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.致癌融合基因 CD74-NRG1 通过 IGF2 自分泌/旁分泌环赋予肺癌肿瘤干细胞样特性。
Cancer Res. 2016 Feb 15;76(4):974-83. doi: 10.1158/0008-5472.CAN-15-2135. Epub 2016 Feb 2.
9
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.18、19和21外显子中不同的表皮生长因子受体(EGFR)基因突变作为非小细胞肺癌(NSCLC)的预后和预测标志物:一项单机构分析
Mol Diagn Ther. 2016 Feb;20(1):55-63. doi: 10.1007/s40291-015-0176-x.
10
Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer.分子通路:肺癌中 NRG1 融合基因的靶向治疗。
Clin Cancer Res. 2015 May 1;21(9):1989-94. doi: 10.1158/1078-0432.CCR-14-0854. Epub 2014 Dec 11.